Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program.
about
Interventions for improving adherence to ocular hypotensive therapyInterventions for improving adherence to ocular hypotensive therapyOveractive bladder: strategies to ensure treatment compliance and adherencePersistence and compliance with medication management in the treatment of overactive bladderPharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladderBehavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial.The effects of drug and behavior therapy on urgency and voiding frequency.Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database.The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trialsNoncompliance in the use of cardiovascular medications in the Medicare Part D populationOnce-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials.OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder.Compliance with once-daily versus twice or thrice-daily administration of antibiotic regimens: a meta-analysis of randomized controlled trials.Urinary incontinence and health-related quality of life among older Americans with and without cancer: a cross-sectional study.Medication adherence in the management of nocturia: challenges and solutions.Current trends in the evaluation and management of female urinary incontinence.A literature review to investigate the link between psychosocial characteristics and treatment adherence in cancer patients.The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis.The effect of spinal cord-injury level on the outcome of neurogenic bladder treatment using OnabotulinumtoxinA.Factors affecting medication discontinuation in patients with overactive bladder symptoms.Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions.Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder.Factors affecting therapeutic compliance: A review from the patient's perspective.Update on the management of overactive bladder: patient considerations and adherenceSocial, Economic, and Medical Factors Associated With Solifenacin Therapy Compliance Among Workers Who Suffer From Lower Urinary Tract Symptoms.Treatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trialPercutaneous tibial nerve stimulation versus electrical stimulation with pelvic floor muscle training for overactive bladder syndrome in women: results of a randomized controlled study.Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.Long-term adherence to antimuscarinic drugs when treating overactive bladder in the older: Subjective reason and objective factors.Novel biomarkers for overactive bladder.Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature.Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder.Oxybutynin gel for the treatment of overactive bladder.Inclusion of compliance and persistence in economic models: past, present and future.Neuromodulation for overactive bladder.Nonbiologic factors that impact management in women with urinary incontinence: review of the literature and findings from a National Institute of Diabetes and Digestive and Kidney Diseases workshop.Persistence with medication and overactive bladder: an ongoing challenge.Cost-Effectiveness Analysis of Anticholinergics Versus Botox for Urgency Urinary Incontinence: Results From the Anticholinergic Versus Botox Comparison Randomized Trial.Does physician specialty affect persistence to pharmacotherapy among patients with overactive bladder syndrome?
P2860
Q24197680-97BFFF1F-3AC2-4481-BF9F-9DB9A3A501EBQ24241641-2A01484C-8115-4697-B238-FF5F91C5F8BDQ26746914-6A8D0868-B3AF-4053-9D53-BB128E4243D4Q26765014-5C01662E-742B-44C7-8FB2-643FC3E765C5Q28275473-A3E35FE9-66CE-4C11-A553-43319C007754Q30430190-7444F07B-A9EB-41B3-A22C-0C048EF35D90Q30431806-AA718F1E-C6C3-4BBC-8586-2EC225071A25Q30647619-D41CB90C-03D5-4DFF-ACC8-0C52C29C7CACQ30894093-0F078510-E973-4B02-94EC-30F5EF8C5D5FQ33567812-C0D95003-EA47-4E76-8601-57DEFA195259Q33806201-B890EFBB-9C44-4BD7-A448-F2BFCC03DB3CQ34804892-B15B0E44-8D2A-4BF5-9D46-661A6141BFA9Q34822693-52DB1E00-43DD-4881-B104-242A052EAC2DQ34908792-973503BB-9546-4155-B30E-D85C50631488Q34982181-087A3125-EF14-4B2B-8C2F-7BBD86E41402Q35113508-58580916-B796-4156-82B0-9B27DA990D44Q35569367-7AAC1B18-BE59-4B8E-BAA7-CDC83EC30AEBQ35798421-A5430C94-9BBD-4712-A435-F946F8FA0B2CQ35898622-36CFA6DA-D535-4D3B-B96D-0FF38E80C035Q36328670-D4FDE67B-81DA-46A0-B52E-E612A0D597EEQ36432096-A41936D2-2948-42CA-96AD-AB5D0ABF7D54Q36528534-40D724A8-119E-4828-AD8C-996A08CF32EAQ36655193-47F8CE09-59CB-48B8-BA1C-C28BF20C596BQ36822915-AE85F53D-268A-4B99-8015-892F5C906BE8Q37283704-ADC67FE1-BAF8-4A0F-B1F2-387B014FE53FQ37373376-6DC0BDBE-C021-4364-91DC-AAA76942844BQ37461417-FB602699-B1B7-4340-BFED-A103EDDD976BQ37626517-96C03896-A1C6-4FF9-8F18-4438650D954BQ37642772-3D3C64A1-7F14-4B74-A67F-28EFF6236665Q37671696-4D776CF5-05F6-4632-8F92-F4A68047A421Q37842130-D062E925-0120-43EE-891C-67E82DD19C59Q37864717-FE241414-355D-4A25-9609-8F7674096340Q37914849-4FB6FED3-8C4E-4100-9566-AEACB786DBEBQ38011202-286BC073-334B-4A83-8961-247CC3D70767Q38048913-8739BA39-16B9-4D3D-B84D-D5478D901EC3Q38118593-CA5AFDDE-6C4F-4BE4-B7D7-0911519C71B3Q38663142-F0AC5123-8D2E-47E4-95B3-0BA0206769C0Q38870480-F4D90A83-01FD-44D6-9DD6-A22D8471D7BCQ39450968-CE510ABA-5E70-45B4-B745-EA1E012499FBQ39475700-98AD49E2-38EB-4886-A1BC-4A85BB9C0AC2
P2860
Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Persistence and adherence of m ...... e california medicaid program.
@en
Persistence and adherence of m ...... e california medicaid program.
@nl
type
label
Persistence and adherence of m ...... e california medicaid program.
@en
Persistence and adherence of m ...... e california medicaid program.
@nl
prefLabel
Persistence and adherence of m ...... e california medicaid program.
@en
Persistence and adherence of m ...... e california medicaid program.
@nl
P1433
P1476
Persistence and adherence of m ...... e california medicaid program.
@en
P2093
Andrew P Yu
Yanni F Yu
P304
P356
10.1111/J.1524-4733.2005.00041.X
P577
2005-07-01T00:00:00Z